In elderly patients with a recent myocardial infarction (MI), 1.8 g of marine n-3 polyunsaturated fatty acids (PUFA) did not lower the incidence of cardiovascular (CV) events or all-cause death after 2 years of follow-up in the placebo-controlled OMEMI trial . The investigators could not rule out an increased risk of atrial fibrillation (AF).
Dr Are Kalstad (Oslo University Hospital, Norway) pointed out that elderly patients have a particularly increased CV risk after MI, even with secondary prevention; yet, this group is underrepresented in clinical trials. The hypothesis of the OMEMI trial (NCT01841944) was that supplementation with marine n-3 PUFA lowers the risk of CV events and total mortality in elderly patients with a recent MI during 2 years of follow-up. Participants were 70–82 years old and had an MI 2–8 weeks prior to inclusion. They were randomised t...
Please login to read the full text of the article.
If you have no account yet, please register now.
« PIONEER III trial: Drug-eluting stents comparable Next Article
Survival of transplant-eligible newly diagnosed MM in FORTE trial »